Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2013

Open Access 01-06-2013 | Research article

Mammographic density and survival in interval breast cancers

Authors: Louise Eriksson, Kamila Czene, Lena U Rosenberg, Sven Törnberg, Keith Humphreys, Per Hall

Published in: Breast Cancer Research | Issue 3/2013

Login to get access

Abstract

Introduction

Mammographic density (MD) is the strongest risk factor for breast cancer. It is also strongly associated with interval cancers (ICs) due to decreased screening sensitivity and possibly by also giving rise to more aggressive tumors. With this information as background, we compared survival in interval and screen-detected cancers, taking MD into consideration.

Methods

The patients were postmenopausal women ages 50 to 74 years who were diagnosed with breast cancer in Sweden between 1993 and 1995. A total of 1,115 women with screen-detected cancers and 285 with ICs had available mammograms. Cox proportional hazards models were used to compare breast cancer-specific survival between interval and screen-detected cancers stratified on MD.

Results

Hazard rates for breast cancer-specific survival were approximately three times higher in ICs than in screen-detected cancers, independent of MD. After adjustment for tumor size, a proxy for time to diagnosis, ICs in nondense breasts still had a statistically significantly increased hazard rate compared to screen-detected cancers in nondense breasts (5-yr survival hazard ratio (HR) 2.43, P = 0.001). In dense breasts, however, there was no longer evidence of a difference in survival between ICs and screen-detected cancers (5-yr survival HR 1.41, P = 0.486).

Conclusions

In nondense breasts, ICs seem to be truly more aggressive than screen-detected cancers. In dense breasts, the poorer prognosis of ICs compared to that of screen-detected cancers may be attributable at least partially to later detection. However, to the best of our knowledge, this study is the first to investigate these relationships, and further studies are warranted to confirm our results.
Literature
1.
McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1159-1169. 10.1158/1055-9965.EPI-06-0034.CrossRefPubMed
2.
Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 1999, 91: 2020-2028. 10.1093/jnci/91.23.2020.CrossRefPubMed
3.
Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V: Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA. 1996, 276: 33-38. 10.1001/jama.1996.03540010035027.CrossRefPubMed
4.
Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ: Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007, 356: 227-236. 10.1056/NEJMoa062790.CrossRefPubMed
5.
Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH: Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003, 5: R129-135. 10.1186/bcr622.CrossRefPubMedPubMedCentral
6.
Fisher ER, Palekar A, Kim WS, Redmond C: The histopathology of mammographic patterns. Am J Clin Pathol. 1978, 69: 421-426.CrossRefPubMed
7.
Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, Lingle WL, Odogwu T, Radisky DC, Visscher DW, Ingle JN, Hartmann LC, Vachon CM: Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat. 2012, 131: 267-275. 10.1007/s10549-011-1727-4.CrossRefPubMed
8.
Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R, Boyd NF: Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev. 2001, 10: 243-248.PubMed
9.
Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N: The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 343-349. 10.1158/1055-9965.EPI-04-0490.CrossRefPubMed
10.
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Chen H, Hallett M, Park M: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008, 14: 518-527. 10.1038/nm1764.CrossRefPubMed
11.
Aiello EJ, Buist DS, White E, Porter PL: Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2005, 14: 662-668. 10.1158/1055-9965.EPI-04-0327.CrossRefPubMed
12.
Sala E, Solomon L, Warren R, McCann J, Duffy S, Luben R, Day N: Size, node status and grade of breast tumours: association with mammographic parenchymal patterns. Eur Radiol. 2000, 10: 157-161. 10.1007/s003300050025.CrossRefPubMed
13.
Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, Tamimi RM: Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 2011, 103: 1179-1189. 10.1093/jnci/djr225.CrossRefPubMedPubMedCentral
14.
Eriksson L, Czene K, Rosenberg L, Humphreys K, Hall P: The influence of mammographic density on breast tumor characteristics. Breast Cancer Res Treat. 2012, 134: 859-866. 10.1007/s10549-012-2127-0.CrossRefPubMed
15.
Boyd NF, Martin LJ, Yaffe MJ, Minkin S: Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 2011, 13: 223-10.1186/bcr2942.CrossRefPubMedPubMedCentral
16.
Heusinger K, Jud SM, Häberle L, Hack CC, Adamietz BR, Meier-Meitinger M, Lux MP, Wittenberg T, Wagner F, Loehberg CR, Uder M, Hartmann A, Schulz-Wendtland R, Beckmann MW, Fasching PA: Association of mammographic density with hormone receptors in invasive breast cancers: results from a case-only study. Int J Cancer. 2012, 131: 2643-2649. 10.1002/ijc.27515.CrossRefPubMed
17.
Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, O'Meara ES, Li CI: Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer. Ann Epidemiol. 2012, 22: 340-348.CrossRefPubMedPubMedCentral
18.
Antoni S, Sasco AJ, dos Santos Silva I, McCormack V: Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis. Breast Cancer Res Treat. 2013, 137: 337-347. 10.1007/s10549-012-2362-4.CrossRefPubMed
19.
Pollán M, Ascunce N, Ederra M, Murillo A, Erdozáin N, Alés-Martínez JE, Pastor-Barriuso R: Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study. Breast Cancer Res. 2013, 15: R9-10.1186/bcr3380.CrossRefPubMedPubMedCentral
20.
Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S: Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat. 1992, 24: 11-16. 10.1007/BF01832353.CrossRefPubMed
21.
Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer. 1999, 81: 339-344. 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6.CrossRefPubMed
22.
Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE: Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res. 2000, 60: 3744-3748.PubMed
23.
Tamimi RM, Hankinson SE, Colditz GA, Byrne C: Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2641-2647. 10.1158/1055-9965.EPI-05-0558.CrossRefPubMed
24.
Livshits G, Malkin I, Williams FM, Hart DJ, Hakim A, Spector TD: Longitudinal study of variation in body mass index in middle-aged UK females. Age (Dordr). 2012, 34: 1285-1294. 10.1007/s11357-011-9299-0.CrossRef
25.
Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S: Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 2001, 285: 171-176. 10.1001/jama.285.2.171.CrossRefPubMed
26.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
27.
Nyström L, Larsson LG, Rutqvist LE, Lindgren A, Lindqvist M, Rydén S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L: Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials: a comparison between official statistics and validation by an endpoint committee. Acta Oncol. 1995, 34: 145-152. 10.3109/02841869509093948.CrossRefPubMed
28.
Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ: The quantitative analysis of mammographic densities. Phys Med Biol. 1994, 39: 1629-1638. 10.1088/0031-9155/39/10/008.CrossRefPubMed
29.
American College of Radiology: The ACR breast imaging reporting and data system. BI-RADS: Mammography. 2003, Reston, VA: American College of Radiology, 3-5. 4
30.
Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA: Accuracy of assigned BI-RADS breast density category definitions. Acad Radiol. 2006, 13: 1143-1149. 10.1016/j.acra.2006.06.005.CrossRefPubMed
31.
Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005, 97: 1195-1203. 10.1093/jnci/dji239.CrossRefPubMed
32.
Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK: Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999, 17: 2334-2340.PubMed
33.
Törnberg S, Codd M, Rodrigues V, Segnan N, Ponti A: Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centres. J Med Screen. 2005, 12: 43-49. 10.1258/0969141053279077.CrossRefPubMed
34.
Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E: Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 2000, 92: 1081-1087. 10.1093/jnci/92.13.1081.CrossRefPubMed
35.
Vachon CM, van Gils CH, Sellers TA, Ghosh K, Pruthi S, Brandt KR, Pankratz VS: Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res. 2007, 9: 217-10.1186/bcr1829.CrossRefPubMedPubMedCentral
Metadata
Title
Mammographic density and survival in interval breast cancers
Authors
Louise Eriksson
Kamila Czene
Lena U Rosenberg
Sven Törnberg
Keith Humphreys
Per Hall
Publication date
01-06-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3440

Other articles of this Issue 3/2013

Breast Cancer Research 3/2013 Go to the issue

Research article

Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort

Research article

The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors

Review

Delivery of gene silencing agents for breast cancer therapy

Review

Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors

Research article

Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors

Viewpoint

Stromal-cell and cancer-cell exosomes leading the metastatic exodus for the promised niche
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits